Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca PharmaphorumThe FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.OncologyRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaphorum The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitationNext: Amgen positions MariTide as potential ‘best monthly’ obesity drug Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
